Related Experiment Videos
Leukoencephalopathy due to oral methotrexate
I González-Suárez1, M J Aguilar-Amat, M Trigueros
1Department of Neurology, IdiPAZHealth Research Institute, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain, igonsua@gmail.com.
Cerebellum (London, England)
|September 27, 2013
Summary
Methotrexate (MTX) can cause rare, severe neurotoxicity like leukoencephalopathy, even at low oral doses for rheumatoid arthritis. Early drug withdrawal is crucial for patient recovery and improved prognosis.
Area of Science:
- Neurology
- Rheumatology
- Pharmacology
Background:
- Methotrexate (MTX) is a primary treatment for rheumatoid arthritis (RA).
- While generally safe, MTX can cause neurotoxicity, ranging from mild to severe encephalopathy, particularly with parenteral administration.
- Severe neurotoxicity, such as leukoencephalopathy, is rarely reported with long-term, low-dose oral MTX.
Observation:
- A 68-year-old male with RA on long-term oral MTX (25 mg weekly) developed progressive dysarthria, ataxia, and cognitive dysfunction.
- MRI revealed cerebellar white matter lesions with diffusion restriction and mild enhancement, consistent with a demyelinating pattern.
- Pharmacogenetic testing showed heterozygous MTHFR and ABCB1 genotypes.
Findings:
- The patient's symptoms improved after MTX discontinuation, indicating MTX-induced leukoencephalopathy.
- Cerebellar involvement in MTX-induced leukoencephalopathy is uncommon, with occipital lobe predilection typically observed.
- The pathogenesis may involve cumulative toxicity to the blood-brain barrier, potentially influenced by genetic factors.
Implications:
- MTX-induced leukoencephalopathy can occur with low-dose oral administration, necessitating vigilance in RA patients.
- Early diagnosis and cessation of MTX are critical for favorable outcomes.
- Further research is needed to elucidate the precise pathogenic mechanisms and the role of genetic polymorphisms in MTX neurotoxicity.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:19Encephalitis l: Introduction
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...